HK1157337A1 - - Google Patents

Info

Publication number
HK1157337A1
HK1157337A1 HK11111670.1A HK11111670A HK1157337A1 HK 1157337 A1 HK1157337 A1 HK 1157337A1 HK 11111670 A HK11111670 A HK 11111670A HK 1157337 A1 HK1157337 A1 HK 1157337A1
Authority
HK
Hong Kong
Prior art keywords
cancer
therapy
compounds
useful
pharmaceutically acceptable
Prior art date
Application number
HK11111670.1A
Other languages
English (en)
Inventor
Maurizio Pulici
Fabio Zuccotto
Alessandra Badari
Stefano Nuvoloni
Giovanni Cervi
Gabriella Traquandi
Sonia Biondaro
Paolo Trifiro'
Chiara Marchionni
Michele Modugno
Original Assignee
Nerviano Medical Sciences Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41059486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1157337(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nerviano Medical Sciences Srl filed Critical Nerviano Medical Sciences Srl
Publication of HK1157337A1 publication Critical patent/HK1157337A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK11111670.1A 2008-07-24 2011-10-28 HK1157337A1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08161076 2008-07-24
PCT/EP2009/059506 WO2010010154A1 (en) 2008-07-24 2009-07-23 3,4-diarylpyrazoles as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
HK1157337A1 true HK1157337A1 (ko) 2012-06-29

Family

ID=41059486

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11111670.1A HK1157337A1 (ko) 2008-07-24 2011-10-28

Country Status (20)

Country Link
US (2) US8541575B2 (ko)
EP (1) EP2324008B1 (ko)
JP (1) JP5385382B2 (ko)
CN (1) CN102105459B (ko)
AT (1) ATE557015T1 (ko)
AU (1) AU2009273197B2 (ko)
BR (1) BRPI0916356B1 (ko)
CA (1) CA2731146C (ko)
CL (1) CL2011000124A1 (ko)
CY (1) CY1117667T1 (ko)
DK (1) DK2324008T3 (ko)
EA (1) EA019722B1 (ko)
ES (1) ES2386408T3 (ko)
HK (1) HK1157337A1 (ko)
HR (1) HRP20120577T1 (ko)
MX (1) MX2011000738A (ko)
PL (1) PL2324008T3 (ko)
PT (1) PT2324008E (ko)
SI (1) SI2324008T1 (ko)
WO (1) WO2010010154A1 (ko)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008001943A1 (es) 2007-07-02 2009-09-11 Boehringer Ingelheim Int Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes.
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
EA019722B1 (ru) * 2008-07-24 2014-05-30 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. 3,4-диарилпиразолы в качестве ингибиторов протеинкиназ
CA2738448A1 (en) 2008-09-29 2010-04-01 Boehringer Ingelheim International Gmbh New chemical compounds
JP2011057661A (ja) * 2009-08-14 2011-03-24 Bayer Cropscience Ag 殺虫性カルボキサミド類
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
US8242260B2 (en) * 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
CA2786509C (en) * 2010-01-27 2016-01-05 Nerviano Medical Sciences S.R.L. Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors
US8865703B2 (en) 2010-03-26 2014-10-21 Boehringer Ingelheim International Gmbh Pyridyltriazoles
EP2552905B1 (en) 2010-03-26 2016-10-05 Boehringer Ingelheim International GmbH B-Raf kinase inhibitors
AR081810A1 (es) 2010-04-07 2012-10-24 Bayer Cropscience Ag Piridinilpirazoles biciclicos
AU2011268906A1 (en) * 2010-06-25 2013-01-31 Novartis Ag Heteroaryl compounds and compositions as protein kinase inhibitors
US9114137B2 (en) 2010-08-03 2015-08-25 Nerviano Medical Sciences S.R.L. Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents
TWI480276B (zh) * 2010-08-27 2015-04-11 Irm Llc 作為蛋白質激酶抑制劑之化合物及組合物
US8710055B2 (en) * 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
ES2693107T3 (es) * 2011-01-25 2018-12-07 The Regents Of The University Of Michigan Inhibidores de Bcl-2/Bcl-xL para su uso en el tratamiento del cáncer
WO2012113774A1 (en) 2011-02-24 2012-08-30 Nerviano Medical Sciences S.R.L. Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors
KR101298651B1 (ko) * 2011-03-16 2013-08-21 연세대학교 산학협력단 효능이 강화된 혈관신생 억제용 약제학적 조성물
WO2013050437A1 (en) 2011-10-06 2013-04-11 Bayer Intellectual Property Gmbh Heterocyclylpyri (mi) dinylpyrazole as fungicidals
RU2627272C2 (ru) 2011-10-06 2017-08-04 Байер Интеллектчуал Проперти Гмбх Гетероциклилпиридинилпиразолы
CA2855243C (en) 2011-11-11 2020-04-14 Novartis Ag Method of treating a proliferative disease
PL2782557T3 (pl) 2011-11-23 2019-03-29 Array Biopharma, Inc. Formulacje farmaceutyczne
KR101668574B1 (ko) 2012-11-02 2016-10-24 화이자 인코포레이티드 브루톤 티로신 키나제 억제제
EP2945940B1 (en) 2013-01-16 2020-07-15 The Regents of The University of Michigan Bcl-2/bcl-xl inhibitors and their use in the treatment of cancer
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
US10822337B2 (en) 2015-04-01 2020-11-03 Rigel Pharmaceuticals, Inc. TGF-β inhibitorC
PE20180686A1 (es) * 2015-08-03 2018-04-23 Glenmark Pharmaceuticals Sa Compuestos nuevos como moduladores de ror gamma
KR20180109842A (ko) 2015-09-16 2018-10-08 록쏘 온콜로지, 인코포레이티드 화합물
CN114591242A (zh) * 2015-12-16 2022-06-07 洛克索肿瘤学股份有限公司 可用作激酶抑制剂的化合物
RU2759669C2 (ru) 2016-06-03 2021-11-16 Аррэй Байофарма Инк. Фармацевтические комбинации
CN109715163B (zh) 2016-09-19 2022-11-22 诺华股份有限公司 包含raf抑制剂和erk抑制剂的治疗组合
CN106883266B (zh) * 2017-01-23 2020-03-17 江苏七洲绿色化工股份有限公司 一种1-(4-氯苯基)-2-环丙基-1-丙酮的制备方法及其中间体
JP7309614B2 (ja) 2017-05-02 2023-07-18 ノバルティス アーゲー 組み合わせ療法
WO2019081477A1 (de) 2017-10-26 2019-05-02 Bayer Cropscience Aktiengesellschaft Substituierte pyrazole sowie deren salze und ihre verwendung als herbizide wirkstoffe
WO2019081485A1 (de) 2017-10-26 2019-05-02 Bayer Cropscience Aktiengesellschaft Substituierte pyrazole sowie deren salze und ihre verwendung als herbizide wirkstoffe
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
CN113226321A (zh) * 2018-10-26 2021-08-06 阿利安制药有限责任公司 吡唑基化合物及其使用方法
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
JP7543319B2 (ja) 2019-06-03 2024-09-02 バイエル・アクチエンゲゼルシヤフト １－フェニル－５－アジニルピラゾリル－３－オキシアルキル酸及び望ましくない植物成長を防除するためのそれらの使用
CN116348458A (zh) 2019-08-14 2023-06-27 因赛特公司 作为cdk2抑制剂的咪唑基嘧啶基胺化合物
CR20220170A (es) 2019-10-11 2022-10-10 Incyte Corp Aminas bicíclicas como inhibidoras de la cdk2
KR102323820B1 (ko) * 2019-10-31 2021-11-08 한국화학연구원 돌연변이형 idh 억제제, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
CN112979613B (zh) * 2019-12-16 2022-04-26 四川大学华西医院 2-(1h-吡唑-3-基)吡啶衍生物及其制备方法和用途
JP2023506301A (ja) 2019-12-19 2023-02-15 バイエル・アクチエンゲゼルシヤフト １，５－ジフェニルピラゾリル－３－オキシアルキル酸及び１－フェニル－５－チエニルピラゾリル－３－オキシアルキル酸並びに望ましくない植物の生長を制御するためのそれらの使用
WO2021120890A1 (en) * 2019-12-20 2021-06-24 Novartis Ag Pyrazolyl derivatives useful as anti-cancer agents
BR112022012674A2 (pt) 2020-01-31 2022-09-06 Bayer Ag Derivados de ácido [(1,4,5-trissubstituído-1h-pirazol-3-il)sulfanil]acético e sais dos mesmos e uso dos mesmos como ingredientes herbicidas ativos
TW202204354A (zh) * 2020-04-02 2022-02-01 美商普雷辛肯公司 用於ｃｓｋ調節之化合物及方法以及其說明
US20230167088A1 (en) 2020-04-29 2023-06-01 Bayer Aktiengesellschaft 1-pyrazinylpyrazolyl-3-oxyalkyl acids and their derivatives, and their use for control of undesired plant growth
MX2023004617A (es) 2020-10-23 2023-05-09 Bayer Ag Derivados de 1-(piridil)-5-azinilpirazol y su uso para el combate del crecimiento de plantas no deseado.
WO2022089604A1 (en) * 2020-10-30 2022-05-05 Novartis Ag New crystalline forms of a kras g12c inhibitor compound
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
AU2022296784A1 (en) 2021-06-25 2024-01-18 Bayer Aktiengesellschaft (1,4,5-trisubstituted-1h-pyrazole-3-yl)oxy-2-alkoxy alkyl acids and their derivatives, their salts and their use as herbicidal agents
WO2023091873A1 (en) * 2021-11-19 2023-05-25 The Board Of Trustees Of The University Of Illinois Gram-negative specific antibiotics sparing effect on gut microbiome
WO2023099381A1 (de) 2021-12-01 2023-06-08 Bayer Aktiengesellschaft (1,4,5-trisubstituierte-1h-pyrazol-3-yl)oxy-2-alkylthio-alkylsäuren und -alkylsäure-derivate, deren salze und ihre verwendung als herbizide wirkstoffe
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2024078871A1 (de) 2022-10-14 2024-04-18 Bayer Aktiengesellschaft 1-pyridyl-5-phenylpyrazolyl-3-oxy- und -3-thioalkylsäuren und derivate und deren verwendung zur bekämpfung unerwünschten pflanzenwachstums

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0001880A3 (en) 1997-05-22 2002-03-28 G D Searle & Co Chicago Substituted pyrazoles as p38 kinase inhibitors
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
EP1456180B1 (en) 2001-12-21 2007-10-03 Vernalis (Cambridge) Limited 3-(2,4)dihydroxyphenyl-4-phenylpyrazoles and their medical use
CA2551948A1 (en) * 2004-01-09 2005-07-28 Novartis Ag Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives as igf-ir inhibitors
EP1917258A2 (en) 2005-08-26 2008-05-07 SmithKline Beecham Corporation Pyrimidinyl-pyrazole inhibitors of aurora kinases
CA2643066A1 (en) * 2006-03-16 2007-09-20 Pfizer Products Inc. Pyrazole compounds
CN103739595A (zh) * 2006-10-02 2014-04-23 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
EA019722B1 (ru) * 2008-07-24 2014-05-30 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. 3,4-диарилпиразолы в качестве ингибиторов протеинкиназ
CA2786509C (en) * 2010-01-27 2016-01-05 Nerviano Medical Sciences S.R.L. Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors
US9114137B2 (en) 2010-08-03 2015-08-25 Nerviano Medical Sciences S.R.L. Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents

Also Published As

Publication number Publication date
PT2324008E (pt) 2012-06-25
AU2009273197A2 (en) 2011-03-10
AU2009273197B2 (en) 2014-01-16
AU2009273197A1 (en) 2010-01-28
US8946250B2 (en) 2015-02-03
CN102105459A (zh) 2011-06-22
BRPI0916356A2 (ko) 2018-08-21
ES2386408T3 (es) 2012-08-20
EA201170249A1 (ru) 2011-10-31
CA2731146C (en) 2016-05-03
DK2324008T3 (da) 2012-07-23
CA2731146A1 (en) 2010-01-28
US20140005150A1 (en) 2014-01-02
MX2011000738A (es) 2011-02-23
PL2324008T3 (pl) 2012-09-28
JP2011528698A (ja) 2011-11-24
US8541575B2 (en) 2013-09-24
EP2324008A1 (en) 2011-05-25
EA019722B1 (ru) 2014-05-30
HRP20120577T1 (hr) 2012-08-31
CN102105459B (zh) 2014-09-10
WO2010010154A1 (en) 2010-01-28
CY1117667T1 (el) 2017-05-17
JP5385382B2 (ja) 2014-01-08
ATE557015T1 (de) 2012-05-15
CL2011000124A1 (es) 2011-05-06
EP2324008B1 (en) 2012-05-09
SI2324008T1 (sl) 2012-08-31
US20110144068A1 (en) 2011-06-16
BRPI0916356B1 (pt) 2022-08-23

Similar Documents

Publication Publication Date Title
HK1157337A1 (ko)
HK1136292A1 (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
WO2009071480A3 (en) Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
UA99141C2 (ru) Замещенные производные индазола, активные в качестве ингибиторов киназы
MX2009006401A (es) Derivados de indazol como inhibidores de cinasa para el tratamiento del cancer.
TW200505924A (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
MXPA06000302A (es) Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
ATE514699T1 (de) Substituierte pyrrolopyrazolderivate als kinaseinhibitoren
UA94097C2 (ru) Пиридил- и пиримидинилзамещенные производной пиррола, тиофена и фурана как ингибиторы киназ
BRPI0413427A (pt) derivados de piridilpirrol ativos como inibidores da cinase
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
MX2009010059A (es) Derivados de quinolina para el tratamiento de enfermedades inflamatorias.
WO2009007749A3 (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
MX2010003927A (es) Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas cinasas b.
TW200510385A (en) Pyrrolo[3, 4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
BRPI0413438A (pt) derivados de pirimidilpirrol ativos como inibidores de cinase
UA102219C2 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы
CU23596A3 (es) Derivados de pirazol-quinazolina y proceso para su preparación
UA100390C2 (en) Pyrrolo[2,3-d]pyrimidin derivatives as protein kinase b inhibitors